Lymphoma, Non Hodgkin Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
- Acute Lymphoid Leukemia
- +4 more
- CD19/CD22 CAR T-Cells
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Recruiting
- Multiple Myeloma
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
2022-04-07
Apr 7, 2022E
Recruiting
- Leukemia, Lymphoid
- +6 more
- Wuhu, Anhui, China
- +21 more
2022-04-06
Apr 6, 2022N
Recruiting
- Hodgkin Disease
- +4 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022N
Completed
- Leukemia
- +3 more
- Bethesda, MarylandNational Cancer Institute (NCI), 9000 Rockville Pike
2022-04-07
Apr 7, 2022C
Recruiting
- Lymphoma, Non-Hodgkin
- +6 more
- CB-010
- +2 more
- Scottsdale, Arizona
- +5 more
2022-04-05
Apr 5, 2022P
Enrolling by invitation
- Lymphoma, B-Cell
- +4 more
- Burbank, California
- +90 more
2022-03-31
Mar 31, 2022H
Recruiting
- Lymphoma, Non-Hodgkin
- RO7227166
- +3 more
- Melbourne, Victoria, Australia
- +11 more
2022-04-01
Apr 1, 2022A
Recruiting
- Advanced Solid Tumor
- +9 more
- Phoenix, Arizona
- +20 more
2022-03-31
Mar 31, 2022J
Completed
- Lymphoma, Non-Hodgkin
- Obinutuzumab and Pixantrone
- Mainz, RLP, GermanyDepartment of Hematology, Oncology and Pneumology; University Me
2022-03-30
Mar 30, 2022B
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (BAY 80-6946)
- Jaú, Sao Paulo, Brazil
- +20 more
2022-03-25
Mar 25, 2022J
Recruiting
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell
- Birmingham, Alabama
- +34 more
2022-03-24
Mar 24, 2022J
Recruiting
- Lymphoma, Non-Hodgkin
- Leukemia, Lymphocytic, Chronic, B-Cell
- New York, New York
- +15 more
2022-03-24
Mar 24, 2022J
Recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Non-Hodgkin
- Duarte, California
- +49 more
2022-03-24
Mar 24, 2022J
Recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, Non-Hodgkin
- New York, New York
- +33 more
2022-03-24
Mar 24, 2022J
Recruiting
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
- New York, New York
- +34 more
2022-03-24
Mar 24, 2022B
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Copanlisib (BAY80-6946)
- +7 more
- Chandler, Arizona
- +200 more
2022-03-23
Mar 23, 2022H
Recruiting
- Lymphoma, Non-Hodgkin
- RO7443904
- +3 more
- Melbourne, Victoria, Australia
- +1 more
2022-03-21
Mar 21, 2022E
Recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- +6 more
- Miami, Florida
- +4 more
2022-03-07
Mar 7, 2022T
Recruiting
- Lymphoma, Non-Hodgkin
- Birmingham, Alabama
- +54 more
2022-03-17
Mar 17, 2022A
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Crizotinib
- +17 more
- Birmingham, Alabama
- +108 more
2022-03-15
Mar 15, 2022C
Active, not recruiting
- Lymphoma, Non-Hodgkin
- Standard of Care
- JCAR017
- Phoenix, Arizona
- +52 more
2022-03-12
Mar 12, 2022C
Recruiting
- Lymphoma, Non-Hodgkin
- +2 more
- Olaparib
- +12 more
- Edmonton, Alberta, Canada
- +9 more
2022-03-14
Mar 14, 2022M
Recruiting
- Hodgkin Disease
- +2 more
- pembrolizumab
- Favezelimab
- Gilbert, Arizona
- +24 more
2022-03-07
Mar 7, 2022U
Active, not recruiting
- Hodgkin Disease
- +8 more
- ATLCAR.CD30 cells
- Chapel Hill, North Carolina
- +1 more
2022-03-02
Mar 2, 2022